Vivani Medical, Inc. — Form 8-K
Filed July 7, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Vivani Medical, Inc. (Seller) agreed to merge with ClearOne Inc. (Parent) via a forward merger of Parent's subsidiary into Cortigent, Inc. (Company). Seller, the sole owner of Company, will receive 12,500,000 shares of Parent Common Stock as consideration. Parent will simultaneously raise $10–15M (2.5–5M units at undisclosed pricing) via Financing, with each unit containing one common share and one warrant exercisable at $10/share for 6 months. The merger is structured as a tax-free reorganization under Section 368(a) of the Code. Seller's shares are subject to staggered lock-ups (50% for 1 year, 50% for 2 years). ThinkEquity LLC is financial advisor to Seller and Company.
Why this rating
Material reverse merger combining medical device companies at $45.9M public market cap; 12.5M new shares (likely 27–40% dilution) is substantial but deal structure neutral-to-negative on valuation. Conditions and financing risk moderate impact.
See more from July 7, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.